A substantive expansion of the Stem Cell Therapeutic and Research Act of 2005. While Sections 1 and 2 remain substantively identical, v2 significantly modifies Section 3 to introduce new provisions for cord blood inventory management, unit transfer, and a definition for high-quality units, alongside extending appropriations. Additionally, v2 adds a new Section 4, establishing a periodic review of the state of science under the national program.
Stem Cell Therapeutic and Research Reauthorization Act of 2026
- Sponsor
- Sen. Reed, Jack [D-RI]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Jun 22, 2026
Bottom line
This bill ensures the continuation and modernization of federal programs supporting stem cell transplantation and cord blood banking, aiming for a more efficient and clinically relevant inventory responsive to scientific progress.
What it actually does
This bill reauthorizes the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory, extending federal funding for these critical programs through fiscal year 2031. It significantly updates the operational guidelines for the National Cord Blood Inventory, shifting its goal from a fixed number of units to a flexible "sufficient supply" determined by the Secretary, and introduces mechanisms for managing non-compliant or non-operational cord blood banks to ensure the continued availability of high-quality units. The bill also mandates enhanced periodic scientific reviews to keep the programs aligned with medical advancements.
Proponents argue
Supporters argue that reauthorization is crucial for continuing life-saving stem cell therapies and research. They contend that the updates to cord blood inventory management will improve efficiency, genetic diversity, and clinical utility by allowing the Secretary to adapt to evolving scientific and clinical evidence, ensuring resources are used effectively to maximize patient access to high-quality units.
Opponents contend
No direct organized opposition is typically raised against the reauthorization of these programs, as they are widely supported for their public health benefits. However, some might express concerns about the broad discretion granted to the Secretary in defining "sufficient supply" and managing the cord blood inventory, potentially impacting smaller banks or leading to subjective decisions.
The bill is very short and can be read and understood quickly, allowing ample time for evaluation of its provisions.
Section 2
Reauthorization of the C.W. Bill Young Cell Transplantation Program
This section reauthorizes the C.W. Bill Young Cell Transplantation Program, which facilitates access to bone marrow and cord blood transplants for patients. It specifically authorizes an appropriation of $33,009,000 for each of fiscal years 2027 through 2031, continuing the program's funding and representing a slight increase over previous authorization levels.
Supporters argue
Supporters argue that this reauthorization is essential to maintain the infrastructure and support necessary for patients to receive critical stem cell transplants, ensuring continuity of care and research in this vital medical field. The program has a proven track record of saving lives and improving health outcomes.
Critics contend
No significant opposition is typically raised against the reauthorization of this program, as its benefits for patients are widely recognized and it enjoys broad bipartisan support.
Tradeoffs
The primary tension is balancing the need for sustained funding for a critical public health program with overall federal budget constraints. The authorized increase reflects a commitment to maintaining and potentially expanding program services.
Section 3
Modernization of Cord Blood Inventory Management
This section amends the Stem Cell Therapeutic and Research Act of 2005 to update the National Cord Blood Inventory. It shifts the inventory goal from a fixed number of 150,000 new units to maintaining "a sufficient supply, as determined by the Secretary, of high-quality cord blood units." It also introduces new provisions allowing the Secretary to transfer units from non-operational or non-compliant cord blood banks to ensure continued availability, and mandates inventory management based on scientific and clinical evidence to maximize utility and genetic diversity.
Section 4
Enhanced Periodic Review of Stem Cell Science
This section amends the Public Health Service Act to require a periodic review of the state of science regarding the use of adult stem cells, high-quality cord blood units, and other emergent technologies in transplantation. This review, which must begin one year after enactment, will inform the Advisory Council on Blood Stem Cell Transplantation and ensure the national program remains current with scientific advancements. The reporting deadline for the Advisory Council is also updated to three years after enactment.
This provision adds a new definition for "high-quality cord blood unit," specifying that it means a unit of cord blood that meets current industry standards and requirements of the Food and Drug Administration.
Section 3(6)(B), amending Section 2(h) of the Stem Cell Therapeutic and Research Act of 2005
Why it matters:It is standard legislative practice to place definitions in a dedicated section of the relevant act, rather than embedding them within the operational provisions.
Case for: Supporters argue that a clear, updated definition ensures that the National Cord Blood Inventory maintains only units that are clinically viable, safe, and effective, aligning with current medical and regulatory best practices. This enhances patient safety and treatment efficacy.
Case against: No specific opposition to defining "high-quality" is expected, as it promotes safety and efficacy. However, debates could arise if the definition were to become overly restrictive or burdensome for cord blood banks, potentially limiting the available inventory or increasing operational costs.
Estimated impact: Ensures the quality and safety of all units within the National Cord Blood Inventory, directly impacting patient outcomes and setting the operational standards for cord blood banks contributing to the national supply.